« Return to News | CROs/Service Providers

Almac doubles analytical capacity, adds 10 jobs

Wednesday, February 15, 2012 02:59 PM

Almac is doubling its analytical capacity at its North American headquarters in Souderton, Penn., increasing the number of employed scientists from 10 to 20.

The 240,000-square-foot facility, built on a 40-acre site, delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients. The facility boasts state-of-the-art analytical labs, supplementing facilities in the U.K.

The additional lab investment will offer new support in the form of polymorph and salt screening, solid form development and the latest bathless dissolution apparatus for rapid and efficient comparative dissolution studies. The last will provide maximum flexibility for developing, validating and running assay, dissolution and stability methods, further complementing the large capacity stability chambers which provide all the required ICH stability conditions.

In addition, the lab will continue to provide support for clinical packaging operations and stand-alone analytical services.

The analytical facility complements Almac’s specialty capabilities, including biocatalysis, radiolabelling, and peptide and protein synthesis. These services are all part of Almac’s comprehensive drug development services, including API and drug product development and GMP manufacture.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.